Antiphospholipid syndrome secondary prevention: Difference between revisions

	Antiphospholipid syndrome Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Antiphospholipid syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic criteria
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Case Studies
Case #1
Antiphospholipid syndrome secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Antiphospholipid syndrome secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Antiphospholipid syndrome secondary prevention
CDC on Antiphospholipid syndrome secondary prevention
Antiphospholipid syndrome secondary prevention in the news
Blogs on Antiphospholipid syndrome secondary prevention
Directions to Hospitals Treating Antiphospholipid syndrome
Risk calculators and risk factors for Antiphospholipid syndrome secondary prevention

← Older edit Newer edit →

VisualWikitext

Revision as of 20:25, 4 April 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

Overview

Secondary Prevention

Long term anticoagulation

Anticoagulation for venous thrombosis:

Anticoagulation for arterial thrombosis:

For patients having definite diagnosis of antiphospholipid syndrome (APS) and previous history of arterial thrombosis are treated with warfarin and low dose aspirin.

Reduction of reversible risk factors

During the perioperative period, this may include minimizing the period when patients are off anticoagulation, initiating early ambulation, and other measures to reduce venous stasis.

Continuation of anticoagulation:

For patients with APS and a history of an unprovoked thrombotic event, lifelong anticoagulation is recommended.

References

Template:WH Template:WS

@@ Line 10: / Line 10: @@
 '''Anticoagulation for arterial thrombosis''':
+For patients having definite diagnosis of antiphospholipid syndrome (APS) and previous history of arterial thrombosis are treated with warfarin and low dose aspirin.
 ===Reduction of reversible risk factors===
@@ Line 15: / Line 17: @@
 During the perioperative period, this may include minimizing the period when patients are off anticoagulation, initiating early ambulation, and other measures to reduce venous stasis.
+=== Continuation of anticoagulation: ===
+For patients with APS and a history of an unprovoked thrombotic event, lifelong anticoagulation is recommended.
-[[Randomized controlled trial]]s have addressed the secondary prevention of thromboses. These trials showed:
-* no benefit from high compared to low intensity warfarin<ref name="pmid 13679527">{{cite journal| author=Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J et al.| title=A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. | journal=N Engl J Med | year= 2003 | volume= 349 | issue= 12 | pages= 1133-8 | pmid=    13679527 | doi=10.1056/NEJMoa035241 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13679527  }}  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15122858 Review in: ACP J Club. 2004 Mar-Apr;140(2):38] </ref><ref name="pmid15869575">{{cite journal| author=Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J et al.| title=A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). | journal=J Thromb Haemost | year= 2005 | volume= 3 | issue= 5 | pages= 848-53 | pmid=15869575 | doi=10.1111/j.1538-7836.2005.01340.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15869575  }} </ref>
-A [[systematic review]] has summarized the research.<ref name="pmid18050167">{{cite journal| author=Ruiz-Irastorza G, Hunt BJ, Khamashta MA| title=A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. | journal=Arthritis Rheum | year= 2007 | volume= 57 | issue= 8 | pages= 1487-95 | pmid=18050167 | doi=10.1002/art.23109 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18050167  }} </ref>
 ==References==